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Renal TGF-j3 regulation in spontaneously diabetic NOD mice with
correlations in mesangial cells. Diabetic nephropathy is characterized by
excessive glomerular matrix accumulation, basement membrane thicken-
ing and sclerosis. Although it is clear that systemic metabolic disturbances
precipitate such renal changes, the signals and pathways involved in this
process are not fully elucidated. Recent evidence suggests that growth
factors/cytokines are intimately involved in the pathogenesis of diabetic
nephropathy. Because of its proscierotic properties, transforming growth
factor-p (TGF-13) is a prime candidate mediator of diabetic nephroscle-
rosis. We examined perfused kidney tissues isolated from spontaneously
diabetic, non-obese diabetic mice (NOD) for TGF-13 content. By using
murine isotype specific TGF-p probes, we demonstrate that within 5 to 10
days of hyperglycuria renal TGF-p2 mRNA and protein content increases.
By immunohistochemical analysis, de novo TGF-p immunoreactivity was
detected within both glomeruli and the interstitium. In order to determine
the signals involved in promoting kidney TGF-13 content in vivo, TGF-13
regulation was examined in renal mesangial cells in vitro. Murine mesang-
ial cells stimulated with glycosylated protein secrete bioactive TGF-13 and
demonstrate a disproportionate increase in the steady state levels of
TGF-p2 mRNA. These data suggest that a major early renal response in
NOD mice to hyperglycemia or to glycosylated proteins is characterized by
increases in TGF-f32.
Diabetes mellitus is currently the most common cause of
end-stage renal disease [1, 2]. The pathological characteristics of
diabetic nephropathy are an expansion of the glomerular extra-
cellular matrix and mesangium, as well as a thickening of the
basement membrane, and occlusion of the glomerular capillary
lumen [3, 4]. Even in the most early clinical stage, diabetic kidney
disease is characterized by widespread glomerular hypertrophy
with a disproportionate increase in matrix and mesangial cell
volume [5, 6]. Over a period of years this process is associated with
the development of hypertension, proteinuria, progressive gb-
merular sclerosis, a loss of glomerular filtration rate and uremia.
Although it is clear that diabetic nephropathy occurs in response
to systemic metabolic alterations, the individual signals and
pathways involved in the pathogenesis of matrix expansion are not
completely understood [7].
In humans, the risk of developing diabetic renal failure corre-
lates with the severity of hyperglycemia and the levels of glyco-
sylated proteins [8]. Elevated glucose levels or advanced glyco-
sylated end-products (AGE) in vitro directly stimulate synthesis of
the mesangial cell matrix proteins: type IV collagen, fibronectin,
laminin and heparan sulfate [9—11]. Although hyperglycemia and
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AGE induce matrix protein specific mRNA transcription and
translation, whether these reflect direct actions or require inter-
mediary regulatory steps has not been defined.
Recent reports propose a role for cytokine/growth factors in the
pathogenesis of diabetic nephropathy [12]. AGE mediated in-
creases in mesangial cell collagen al(IV) mRNA levels in vitro
was blunted by antibodies to platelet-derived growth factor
(PDGF) [13]. The transforming growth factor beta (TGF-13)
family of cytokines is also critically involved in extracellular matrix
accumulation and scarring observed with tissue injury repair [141.
All three mammalian isoforms of TGF-13 (TGF-pl, TGF-/32 and
TGF-p3) induce the synthesis of matrix component proteins, as
well as diminish the production of matrix degrading proteases
[15—21]. TGF-13 has been implicated in mediating renal disease in
rats following immune-mediated injury [22]. Furthermore, inhibi-
tion of TGF-/3 activity in a rat model of immune complex nephritis
prevented glomerular scarring [23, 24]. Similarly, in streptozoto-
cm (STZ)-induced diabetic rats, glomerular TGF-131 mRNA and
protein levels increase following the onset of hyperglycemia [25,
26]. In humans, renal tissues with advanced diabetic nephropathy
contain the normally absent TGF-f31 product [25]. The relative
contributions of the other TGF-/3 isoforms to the pathogenesis of
diabetic nephropathy are as yet unclear. Moreover, the timing of
renal TGF-f3 production following the onset of spontaneous
hyperglycemia rather than that induced by the nephrotoxic com-
pound, STZ, has not been evaluated [27]. Finally, the relationship
between AGE and renal mesangial cell TGF-p metabolism has
not been delineated.
To address these issues, we examined renal tissues for TGF-j3
content in the NOD mouse model of spontaneous human Type 1
diabetes (IDDM) [28]. In this report, we demonstrate that
TGF-132 mRNA and protein content disproportionately increases
in NOD renal tissues after only 5 to 10 days of hyperglycuria.
AGE stimulation of autoimmune NOD and normal BALB/c
mesangial cells results in secretion of bioactive TGF-f3. Moreover,
AGE stimulation of mesangial cells leads to an elevation in the
steady state levels of all three TGF-p mRNA species but with the
greatest increase noted in TGF-f32 content.
Methods
Animals
Breeding pairs of NOD (K', I-A7, I-E, D1') were purchased
from Taconic Farms (Germantown, New York, USA) and bred at
the University of Virginia. BALB/c mice were purchased from
Jackson Labs (Bar Harbor, Maine, USA). Animals were housed in
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standard laboratory cages under viral free conditions and fed ad
libitum normal mouse chow. Mice had free access to unlimited
supplies of tap water. Serological testing perfonned by the
University of Virginia Comparative Animal Facility confirmed
that NOD mice were free of common murine pathogens. The
cumulative incidence of IDDM by six months of age among NOD
breeding pairs was 96% in females and 22% in males. Mice were
routinely monitored for glycosuria twice weekly. The day that
glycosuria was first noted was considered as day 1 of diabetes. To
avoid the possibility of severe metabolic disturbances, one group
of NOD mice received a standard dose of 10 U humulin regular
insulin as a single daily subcutaneous injection. The degree of
glycosuria was not altered in the insulin treated group.
Reagents
The following reagents were purchased from manufacturers:
Dulbecco's minimum essential medium (DMEM), glucose-free
RPMI medium, HEPES buffer, sodium pyruvate, penicillin-strep-
tomycin, nonessential amino acids, trypsin-EDTA, calf serum-IE,
(GIBCO, Grand Island, New York, USA); Tween-20, 2-mercap-
toethanol (2-ME), aprotinin, leupeptin, pepstatin, EDTA, EGTA,
phenylmethylsulfonylfiouride (PMSF), soybean trypsin inhibitor,
benzamidine and antipain, lyophilized human serum albumin,
angiotensin II (Ang II) (Sigma, St. Louis, Missouri, USA);
3H-thymidine (New England Nuclear, Boston, Massachusetts,
USA); sodium dodecyl sulfate (SDS; USB, Cleveland, Ohio,
USA); epidermal growth factor (EGF; Collaborative Research,
Lexington, Massachusetts, USA); recombinant human insulin
(UpJohn Pharmaceuticals, Kallamazo, Michigan, USA); NIH 3T3
fibroblast and CCL-64 mink lung epithelial cell lines (ATCC,
Rockville, Maryland, USA); chemiluminescent substrate (ECL,
Amersham, Arlington Heights, Illinois, USA); ABC kit (Vector
Labs, Burlingame, California, USA); Permount (Fisher Sci., Fair
Lawn, New Jersey, USA); nonpyrogenic saline (NS) (Abbott
Labs, North Chicago, Illinois, USA); polyclonal anti-TGF-f31
specific antiserum (R&D Systems, Minneapolis, Minnesota,
USA).
The following reagents were generously provided as gifts:
polyclonal rabbit antiserum specific for the unique first 29 amino
acids of bovine-bone derived TGF-!32 (R34) [29], monoclonal
antibody (Mab) 1D11.16 directed against TGF-131 and TGF-j32
[30], an isotype specific IgGi irrelevant control Mab KJ65,
recombinant human TGF-131 (rTGF-/31) and recombinant human
TGF-/32 (rTGF-2) (Dr. Jim Dasch and Wendy Waegell, Celtrix
Labs, Palo Alto, California, USA); recombinant human interleu-
kin-la (rIL-la) (Dr. Peter Lomedico, Hoffman-LaRoche, Nutley,
New Jersey, USA); cDNA probes specific for murine TGF-131,
TGF-/32, and TGF-j33 (Dr. Harold Moses, Vanderbilt Univ.,
Nashville, Tennessee, USA) [31—33].
RNApreparation and Northern blot analysis
After induction of anesthesia, NOD kidneys were perfused with
phosphate-buffered saline (PBS) (0.15 M NaCl, 0.02 M P04, pH
7.2) as previously described [34]. The renal cortices were dissected
away from the medullas and were homogenized using a tissue
homogenizer (Tekmar, Cincinnati, Ohio, USA). Total RNA was
isolated using the acid-guanidium thiocyanate-phenol-chloroform
method of Chomczynski and Sacchi and quantitated spectropho-
tometrically [35]. Plastic adherent cultured mesangial cells were
harvested following five minutes of cold trypsinization and sub-
jected to similar RNA extraction.
For Northern blot analysis, total RNA samples (15 to 20
g/1ane) were electrophoresed through a 0.8% agarose gel con-
taining 0.5% formaldehyde and stained with ethidium bromide.
RNA was transferred electrophoretically overnight (ON) onto
nylon membranes (Gene Screen, New England Nuclear) in 0.04 M
Tris-acetate 0.001 M EDTA pH 8.0 (TAE) buffer. Complete
transfer was confirmed by the appearance of visibly stained RNA
on the membranes and an absence of residual RNA in the gel.
Isoform specific TGF-13 [a-32P] labeled probes were generated to
nonconserved regions of TGF-j3. TGF-pl, TGF-132 and TGF-p3
plasmids were subjected to endonuclease digestion with Smal,
XholIEcoRt and EcoRl/Smal, respectively. The corresponding
974, 442, and 609 bp fragments were purified by gel electrophore-
sis and labeled with [a-32P] deoxycytidine (dCTP) (New England
Nuclear) by random primer extension. Nylon membranes were
prehybridized ON in a 1 mi EDTA, 0.5 M NaH2PO4, pH 7.2, 7%
SDS solution at 65°C, followed by ON hybridization in 1 mr'i
EDTA, 0.5 M NaH2PO4, 7% SDS at 65°C. Blots were washed
twice under high stringency (final wash: 60°C in 1 mtvi EDTA, 40
mivi NaPO4, 1% SDS) for 30 minutes and autoradiographed by
standard techniques using intensifying screens. Band intensities
were quantitated by densitometry (Lightning Scan, Thunderware,
Orinda, California, USA) and analyzed with a software program
(Scan Analysis, BioSoft, Cambridge, UK). Band intensities were
recorded as Arbitrary Units (AU) corresponding to the relative
areas under the densitometric peaks.
To calculate relative amounts of mRNA, individual TGF-/3 and
actin band densities were compared to that of the 18S RNA band
scanned on a photographic negative image of the ethidium stained
gel. The results are given as ratios of band density to the 18S
density. The autoradiograms were developed within 2 to 10 days
to avoid oversaturation. Blots were considered negative for spe-
cific signal if bands were not visualized after 20 days of exposure.
By comparing individual signal intensities to the 18S band,
variations in loading, as well as, alterations in "housekeeping"
gene mRNA content induced by hyperglycemia were taken into
account in calculating changes TGF-j3 mRNA levels.
Protein preparation and Western blot analysis
Renal cortices from saline perfused NOD kidneys were homog-
enized in 0.25 M sucrose, 10 mM Tris HCI solution containing the
protein inhibitors aprotinin, leupeptin, pepstatin, benzamidine
and antipain at 10 gIml, as well as, 5 mrvi EDTA, 5 mM EGTA,
0.1 mM PMSF, 5 mg/mI soybean trypsin inhibitor. The samples
were centrifuged at 30,000 X g for 10 minutes and the supernatant
was further ultracentrifuged at 130,000 x g for one hour. The
pellet was collected and stored at —70°C in the sucrose/Tris!
inhibitor solution. Protein concentration was determined by the
method of Bradford [36]. Proteins (100 g/1ane) were separated
under nonreduced conditions by 12% SDS-PAGE and transferred
electrophoretically onto nitrocellulose membranes (BioRad).
Equivalent protein loading was confirmed by Ponceau staining.
Blots were washed several times in Tris-buffered saline (TS: 150
mM NaC1, 20 mtvi Tris HCI, pH 7.4) containing 5% non-fat
powdered milk and 0.1% Tween-20 (PMT solution), incubated
with either anti-TGF-132 (R34) or anti-TGF-131 specific antiserum
at 1:250 dilution for one hour at RT and washed three times with
PMT. The blots were interacted with a horseradish peroxidase
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conjugated goat anti-rabbit antibody (Sigma) for one hour,
washed in PMT, reacted with chemiluminescent substrate and
developed by standard autoradiography. For inhibition assays,
R34 antiserum was first incubated with equal amounts (1 tg) of
either rTGF-131, rTGF-J32 or rIL-lcw in 20 jxl 5% bovine serum
albumin (BSA)/PBS solution for three hours at 37°C followed by
Western analysis as described above.
Immunohistochemisty
Saline perfused kidneys were incubated in a 30% sucrose, 0.12
M NaPO4 buffer for 12 hours, fixed in 3% formalin, dehydrated
through graded ethanols, cleared in xylene and embedded in
paraffin. Tissue sections were mounted on polylysine slides,
deparaffinized in xylene and rehydrated in graded ethanol to PBS.
Endogenous peroxide activity was blocked for 30 minutes in a
methanol/peroxide (18:1 vol/vol ratio) solution. Nonspecific bind-
ing was blocked with 1.5% Avidin/Biotin, 10% normal goat serum
(Vector) in a 3% bovine serum albumin (BSA)IPBS solution
(GBP) for one hour followed by staining with 20 jg/ml anti-
TGF-/3 Mab, 1D11, in GBP for one hour. The slides were washed
in PBS, counterstained with a biotin labeled anti-mouse IgG rat
antiserum (Vector), washed and incubated in ABC solution for 30
minutes (Vector). The slides were developed for one minute in
diaminobenzidine (DAB; Vector), water rinsed for 15 minutes,
dehydrated in graded ethanol, cleared in xylene and mounted with
Permount (Fisher).
Mesangial cell culture and characterization
With slight modifications, mesangial cells were isolated from
BALB/c and NOD glomeruli according to previously published
techniques [37]. Ten-week-old mice were sacrificed by cervical
dislocation and the kidneys were removed under sterile condi-
tions. The cortex was diced into small pieces and passed through
a sterile stainless steel metal sieve (opening size 250 m; Newark
Wire Cloth Co., Newark, New Jersey, USA). The tissue homoge-
nate was further dissociated by passage through a 25 g needle
(Becton-Dickenson). The tissue was centrifuged at 500 X g for
five minutes, resuspended in D-valine (100 g/ml) substituted
DMEM containing 20% CS-IE, 10% Na pyruvate, iO M 2-ME,
30 ng/ml EGF, 1 U/mI insulin, 500 mg/mI D-glucose final concen-
tration and plated into 96-well fiat bottom tissue culture plates
(Nunc, Naperville, Illinois, USA). Plates were left undisturbed for
14 days and examined for cellular outgrowths. Wells containing
only isolated glomeruli were harvested using mild tiypsin diges-
tion and expanded by passage into T-25 flasks (Nunc). To prevent
fibroblast growth, cells were maintained throughout in D-val
substituted DMEM. Mesangial cells were characterized and ex-
amined for their response to glycosylated human albumin be-
tween passages 8 and 10.
To analyze mesangial cell mRNA response to AGE, noncon-
fluent adherent mesangial cell cultures were washed extensively in
DMEM alone and switched for three days into serum free culture
medium lacking insulin and EGF. Cultures were washed daily and
fresh serum free medium was added. Mesangial cell cultures were
either left untreated or were exposed to normal human albumin
or AGE (final concentration 200 tg/ml) for 16 hours, suspended
by mild trypsin digestion and harvested for total RNA. AGE were
prepared according to the methods of Makita et a! [38]. Human
albumin (50 mg/ml, 250X) was dissolved in NS containing 20 mM
glucose for at least 4 weeks at 37°C. Control normal albumin was
similarly diluted in NS without glucose and incubated at 37°C.
Compared to normal albumin, glycosylated albumin demon-
strated a typical increased (1.5 fold) fluorescence pattern at
excitation/emission wavelengths of 335/385 and 360/450 [38—40].
To detect TGF-13 secretion, mesangial cells were harvested,
washed extensively in glucose-free RPMI, and plated at 1 X i05
cells/well in flat-bottom tissue culture plates (CoStar, Cambridge,
Massachusetts, USA). Mesangial cells were cultured for 24 hours
in serum-free RPMI medium containing either low glucose (L)
(100 mg%), high glucose (H) (400 mg%), normal human albumin
(HSA) (200 jLg/ml) or glycosylated human albumin (AGE) (200
gIml). Culture supernatants were harvested and tested for
TGF-J3 activity in a standard CCL-64 mink lung bioassay per-
formed according to the method of Lotz, Kekow and Carson [41].
CCL64 cells were suspended by mild trypsin/EDTA digestion
(Gibco), washed twice in DMEM, resuspended in DMEM 1%
FCS, and plated at io viable cells/well in 96-well flat bottom
tissue culture plates (CoStar). After 24 hours, the medium was
removed and the samples to be assayed for TGF-13 content were
added. After 24 hours, the wells were pulsed with [3H}-thymidine
(1 Ci/weIl). The plates were harvested 24 hours later onto glass
fiber filters and [3H]-thymidine incorporation determined using a
Wallac Beta Plate Scintillation Counter [42]. To reverse the
inhibitoiy effects of mesangial cell supernatants on CCL-64 cell
growth, AGE-stimulated mesangial cells were cultured in the
presence of Mabs 1D11.16 and KJ65 (30 g/ml). Supernatants
were harvested and tested for TGF-f3 bioactivity as described
above.
Mesangial cells and 3T3 fibroblasts were evaluated for their
ability to proliferate in D- or L-valine substituted DMEM by
standard 3H-thymidine incorporation. Both cell types were sus-
pended by mild trypsin digestion and viable cell numbers were
determined by Trypan blue exclusion. Cells were washed in serum
free DMEM, resuspended in either D- or L-valine containing
DMEM and plated at 2 X iO cells/well in 96-well flat bottom
tissue culture plates. One 1LCI of [3H]-thymidine was added to
each well for 24 hours and harvested as previously described.
For immunofluorescence analysis and response to Ang II
mesangial cells were grown to confluence on tissue culture
chamber slides (Nunc). Cells were fixed in cold acetone for 15
minutes, washed in PBS, interacted with the specific primary
antibody for 45 minutes, washed in PBS and incubated with
fluorescein (FITC) conjugated second step antibody for 30 min-
utes. Cover slips were mounted and slides were examined for
fluorescence. Primary antibodies included: rabbit anti-human
factor Vill-related antigen (Dako, Santa Barbara, California,
USA), mouse anti-human desmin (Dakopatts, Denmark). For
contraction studies, nonconfluent mesangial cells grown on cham-
ber slides were interacted with 1 pm Mg II. As previously
described, cell contraction performed in the presence of calcium
and serum was evaluated by phase contrast microscopy at room
temperature [37].
Glycated hemoglobin assay
Total glycated hemoglobin was measured by standard binding
assays to agarose bound boronate groups (Glyc-Aflin GHb,
Isolab, Akron, Ohio, USA) [43]. Blood collected from NOD mice
within 10 days of the onset of glycosuria and from normoglycemic
NOD mice was subjected to glycoHgb determination. All assays
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Fig. 1. Northern blot analysis of total RNA
isolated from renal cortices of normoglycemic
(N), diabetic (D) and insulin treated diabetic
(D+I) NOD mice. Specific TGF-1 (panel 1),
TGF-132 (panel 2), and p-actin (panel 3) cDNA
probes were used to detect respective mRNA
contents on a Northern blot containing total
RNA harvested from NOD kidney cortices. No
significant changes were noted in TGFf3-1 and
actin mRNA content in diabetic NOD mice.
Insulin treatment led to a slight increase in
actin mRNA content. Compared to normal
NOD mice, the TGF-132 signal intensity was
markedly augmented in both diabetic and
insulin treated diabetic NOD mouse kidney
cortical tissues. Total RNA loaded was
determined by ethidium bromide staining prior
to transfer (panel 4). Following transfer no
visible RNA remained within the gel.
were performed in a blinded fashion by the Clinical Labs,
University of Virginia.
Statistics
Data were analyzed using an analysis of variance by the Fisher
protected least significant differences method (ANOVA).
Results
Diabetes increases NOD renal cortical TGF-p2 mRNA content
NOD mice sacrificed 5 to 10 days following the onset of
spontaneous glycosuria were examined for renal cortical TGF-p
mRNA content. TGF-131 mRNA was readily detectable in renal
cortical tissues harvested from normal and hyperglycemic animals
(Fig. 1, panel 1). Compared to values obtained in nondiabetic
NOD mice, the ratios of the TGF-31 to 18S mRNA signal
intensities in diabetic or insulin treated diabetic NOD mice were
not significantly altered [mean SD, normal (N), 6.59 0.51;
diabetic (D), 5.38 0.64; diabetic plus insulin (D + I) 8.19
0.72; P = NS amongst the groups]. As shown in panel 2, TGF-f32
mRNA signals typically appear as 2 to 4 bands located at
approximately 28S RNA marker [431. By densitometric analysis,
compared to normoglycemic NOD mice the combined TGF-f32
signal intensity in diabetic mice increased by 82% after the onset
of diabetes (N 6.33 0.96 vs. D 11.58 1.86; P < 0.05). In
diabetic NOD mice receiving insulin, the TGF-/32 mRNA content
increased by 199% (N vs. D+I 18.93 1.02; P < 0.05).
To determine if changes in TGF-p2 mRNA content were due to
nonspecific alterations in steady-state total mRNA induced by
diabetes or insulin therapy, the same blot was rehybridized with a
f3-actin probe (panel 3). Compared to nondiabetic NOD mice, no
difference in actin mRNA content was noted in diabetic NOD
mice; however, insulin therapy resulted in a 68% increase in the
steady state level of actin mRNA (N 20.83 3.21; D 20.86 2.55;
D+I 35 0.72; P < 0.05 N vs. D+I). When the blot was
rehybridized to a TGF-133 specific eDNA probe, no signal could
be detected (data not shown).
Diabetes increases NOD renal TGF-p2 protein content
To demonstrate that the increase in renal TGF-f32 mRNA
content was associated with a concominant increase in TGF-132
product, renal cortical protein homogenates were subjected to
Western blot analysis using a TGF-f32 specific antiserum (R34).
Analysis of recombinant TGF-/3 proteins typically demonstrate
specific bands located at 12.5 kDa, 25 kDa and at very high
molecular weights representing monomers, dimers and polymers
of TGF-p, respectively. Seventeen NOD mice were studied and
representative Western blots from two experiments are shown in
Figure 2. In all cases, renal tissues harvested from diabetic (D)
Pankeiycz et al.: Renal TGF-/3 content in murine diabetes 751
1
2
3
4
Exp 2Exp 1
0 z 0 zr r
a—ta
La
A
4-43
— 29
—18
—14
—18
752 Pankeitycz et aL: Renal TGF-13 content in murine diabetes
Fig. 2. Western blot analysis of renal cortical
proteins for TGF-132. The results of two separate
experiments are shown as Exp. 1 and Exp. 2.
Renal cortical proteins harvested from
normoglycemic (N), diabetic (D) and insulin
treated diabetic (D+I) NOD mice were
separated by SDS-PAGE, blotted onto
nitrocellulose and probed with an anti-TGF-/32
specific antiserum R34 (1:250 dii). In contrast
to normoglycemic NOD mice, the renal tissues
of diabetic (D & D+I) mice contained greater
amounts of the monomeric (14 kDa) and
dimeric (24.6) forms of TGF-p2.
mice contained larger amounts of monomeric (14 kDa) and
dimeric (24.6 kDa) forms of TGF-p2 protein compared to nor-
moglycemic (N) NOD mice. Moreover, renal TGF-j32 protein
content in insulin-treated hyperglycemic NOD mice (D+I) was
similarly elevated.
To confirm that the 14 and 24.6 kDa bands observed in these
studies contained TGF-32, a competitive Western analysis was
performed using R34 antiserum (Fig. 3). R34 antiserum was
preincubated with equal amounts of rTGF-f31, rIL-la and
rTGF-132 prior to its application onto protein blots. Compared to
control uninhibited R34 binding to diabetic NOD renal proteins
(lane 1), rTGF-/32 competed for the binding of R34 antiserum to
both the 14 and 24.6 kDa bands (lane 4). Recombinant TGF-131
was incapable of competing for R34 binding to either band (lane
2). Using the unrelated cytokine, rIL-la, a slight but incomplete
amount of inhibition was noted to the 24.6 kDa but not to the 14
kDa band (lane 3).
NOD renal cortical proteins were also examined by Western
blot analysis using a specific antiserum for TGF-j31 content.
Compared to normal tissues (N), in three separate experiments
diabetic (D) NOD renal protein samples demonstrated a faint
band at 14 kDa when probed with an anti-TGF-131 antiserum (Fig.
4, lanes 1 and 2). As a control, anti-TGF-131 antiserum detected 50
ng of rTGF-1 added to normoglycemic NOD renal proteins
(lane 3, T131). In these same tissue samples using the R34
antiserum, renal TGF-132 protein was again increased in diabetic
(D) compared to normal (N) NOD mice (lanes 4 and 5).
Following longer exposure, a 25 kDa TGF-132 band was detected
only in the diabetic sample (lane 5).
TGF-/3 localizes to both the glomerulus and interstitium
Kidney sections were obtained from normoglycemic and dia-
betic NOD mice 10 days following the onset of glycosuria.
Sections were stained with the pan-TGF-p Mab, 1D11 [30].
Normoglycemic NOD renal tissues failed to demonstrate any
immunoreactivity with 1D11 (Fig. 5A). Kidney tissues harvested
from very early diabetic NOD mice demonstrated intense but
focal areas of staining within interstitium (Fig. 5B). A less intense
staining pattern was observed within glomeruli (Fig. SC). Approx-
imately 50% of glomeruli from diabetic NOD mice contained
TGF-13 immunoreactivity.
AGE stimulation increases mesangial cell TGF-/32 mRNA content
and protein secretion
The presence of TGF-3 glomerular immunoreactivity
prompted us to examine mesangial cells as a potential source of
the increased TGF-13 levels observed in vivo. Both NOD and
1234
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Fig. 3. Competitive Western blot analysis of R34 binding to renal cortical
tissues. Nitrocellulose blots containing diabetic NOD kidney cortical
proteins were interacted with R34 antiserum alone (lane 1), or following
preincubation of R34 with rTGF-131 (lane 2), rIL-la (lane 3) or rTGF-2(lane 4). rTGF-131 failed to inhibit R34 binding to either the 14 or 24.6
kDa bands. ilL-la had only minimal inhibitory activity against the 25 kDa
band. In contrast, rTGF-132 completely inhibited the binding of R34 to
both the 14 and 24.6 kDa bands.
aTGF31 aTGFI32
BALBIc mesangial cells in culture grew in a typical stellate shape
with prominent cellular projections. Mesangial cells demonstrated
a characteristic fibrillar pattern of immunostaining for desmin
which was absent in control NIH 3T3 fibroblasts. Immunofluores-
cence for Factor Vill-related antigen was negative in both
mesangial and fibroblast cells (data not shown). As visualized by
phase microscopy, mesangial cells responded to Ang II stimula-
tion with contraction and a retraction of cellular projections
lasting approximately 30 minutes. To further characterize our
renal-derived cell lines, mesangial cells and 3T3 fibroblast cultures
were tested for growth sensitivity to D-valine substituted DMEM.
As previously demonstrated, 3T3 fibroblasts failed to grow in
D-valine containing DMEM compared to L-valine (3H-thymidine
incorporation CPM mean SD; L-val 348,352 67,930 vs. D-val
89,530 35,727; P < 0.05). In comparison, renal-derived mesang-
ial cells demonstrated no growth inhibition in D-valine substituted
medium (L-val 40,112 3,330 vs. D-val 42,279 11,893;P = NS).
Fig. 4. Western blot analysis of renal cortical proteins for TGF-f31 and 2.
Renal cortical proteins harvested from normoglycemic (N) and diabetic
(D) NOD mice were separated by SDS-PAGE, blotted onto nitrocellulose
and probed with an anti-TGF-131 (aTGF-131) specific antiserum or R34
(aTGF-132) (1:250 dil). In contrast to normoglycemic NOD mice, diabetic
(D) mice contained only trace amounts of TGF-j31 signal at 14 kDa (lane
1 vs. 2). When 50 ng of rhTGF-131 was added to the normal protein
sample, an easily detectable signal was noted at 25 kDa (lane 3, T/31). In
contrast, diabetic renal tissues contained a greater amount of TGF-p2
(lane 4 vs. 5).
Supernatants harvested from mesangial cell cultures grown in
either low (L, 100 mg%) or high (H, 400 mg%) D-glucose
containing medium or stimulated with normal human albumin
(HSA) or glycosylated human albumin (AGE; 200 j.rml) were
tested for TGF-f3 bioactivity. Only AGE stimulated mesangial cell
supernatants harvested from BALB/c (Fig. 6A) and NOD (Fig.
6B) inhibited the growth of the TGF-13-sensitive CCL-64 cell line.
The inhibitory effects of AGE-stimulated mesangial cell culture
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Fig. 5. Immunohistochemical analysis of
nonnoglycemic and diabetic NOD renal tissues for
TGF-1. Kidney sections obtained from
nonuoglycemic NOD mice and interacted with
the monoclonal anti-TGF-/3 antibody, 1D11,
failed to demonstrate any staining (A). Diabetic
NOD renal tissues were positive for 1D11 binding
detected as a brown color reaction. TGF-f3 was
detected in two patterns consisting of both an
intense focal interstitial staining (B) and a less
intense focal pattern within glomeruli (C).
Reproduction of color photos was made possible
by an educational grant from Bristol Meyers..
Squibb Corporation, Princeton, NJ.
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Fig. 6. TGF- CCL -64 bioassay. Mesangial
cells grown under serum free conditions were
stimulated with either low glucose medium (L)
(100 mg%), high glucose medium (H) (400
mg%), normal human albumin (HSA; 200 j.g/
ml) or glycosylated human albumin (AGE; 200
jsglml). The resultant culture supernatants were
added to CCL-64 cells. After 24 hours, the
plates were pulsed with 3H-thymidine and
harvested. In both BALB/c (A) and NOD (B)
mesangial cells, only AGE stimulated cultures
inhibited the growth of CCL-64 cells. *P < 0.01
vs. control (C) no supernatant containing
cultures.
Fig. 7. Anti-TGF-13 antiserum reverses AGE
stimulated mesangial supernatant TGF-13
bioactivity. AGE-stimulated BALB/c mesangial
cells were cultured in the presence of 1D11
Mab (30 jsglml) or an irrelevant IgGi Mab,
KJ65 (30 jig/mI). Resultant supernatants were
added to CCL-64 cells, pulsed and harvested as
in Fig. 6. The anti-TGF-13 Mab, 1D11,
completely abrogated the inhibitory effect of
AGE-stimulated mesangial cell supernatants.
< 0.05 vs controls containing no supernatants
(C).
supernatants were completely neutralized by the anti-TGF-13
Mab, 1D11, whereas, the isotype-matched control Mab, KJ65, was
without effect (Fig. 7 A, B).
To determine if AGE stimulation increased mesangial cell
TGF-13 mRNA levels as well as TGF-f3 secretion, nonconfluent
mesangial cells were examined for their response to AGE and
HSA stimulation. RNA samples harvested from BALB/c mesang-
ial cells grown in serum free medium and stimulated with normal
albumin contained all three isoforms of TGF-f3 (Fig. 8, lane 1,
panels I, II, III). Allowing for differences in loading, the mesangial
cell steady state content of TGF-131 and TGF-f33 mRNA in-
creased by less than 60% following interactions with AGE (lane 2,
panels I and III). In contrast, AGE stimulation resulted in a
threefold increase in the steady state levels of mesangial cell
TGF-f32 mRNA (panel II). In a similar assay performed with
NOD derived mesangial cells, AGE protein stimulation led to a
25% increase in TGF-J31, a 50% increase in TGF-133 and a
twofold increase in TGF-/32 mesangial cell steady-state mRNA
content (Fig. 9, panels I, III and II, respectively).
The above data indicate that in vitro, glycated proteins may be
a major positive stimulus for mesangial cell TGF-13 synthesis and
secretion. To determine if glycated proteins are present in NOD
mice in vivo, blood samples were collected from five normoglyce-
mic and five diabetic NOD mice within 10 days of the onset of
glycosuria. Compared to normals, diabetic NOD mice had ele-
vated circulating levels of total glycated hemoglobin (normal 2.6
0.5% vs. diabetic 6.4 2.6%; P < 0.01).
Discussion
The present studies were conducted to explore the possibility
that renal expression of the prosclerotic cytokine, TGF-/3, is
increased in vivo following the onset of spontaneous hyperglyce-
mia. We have studied the NOD mouse strain, considered to be a
relevant model of spontaneous human Type I diabetes [28]. NOD
mice offer several distinct advantages in the study of diabetic
nephropathy. Compared to other animal models, NOD mice
spontaneously develop autoimmune diabetes and hyperglycemia
obviating the need to administer the nephrotoxic compound, STZ.
NOD mice share with patients many of the immunological and
genetic markers of IDDM. Furthermore, NOD mice develop
proteinuria and the earliest changes of diabetic nephropathy [44].
TGF-13 is a likely candidate cytokine involved in the pathogen-
esis of diabetic nephropathy. TGF-p induces matrix protein
synthesis in many cell types including renal mesangial cells [45].
Furthermore, TGF-/3 augments expansion of extracellular matrix
by simultaneously increasing the production of protease inhibitors
while decreasing the synthesis of matrix degrading proteases
[19—221. These effects prevent normal tissue remodeling processes
and may lead to typical diabetic nephrosclerotic changes. Border
and colleagues have shown that, in rats, TGF-131 is a critical
signal-promoting glomerular scarring following an immune injury
[23, 24]. The levels of renal TGF-pl mRNA and several of the
genes influenced by TGF-f3, that is, collagen, laminin are also
increased in STZ-induced diabetic rat model [25, 26]. However,
185-
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Fig. 8. Northern blot analysis of mesangial cell TGF-13 mRNA content following stimulation with AGE. RNA isolated from BALB/c mesangial cells was
separated on an agarose gel and blotted onto a nylon screen. The same blot was rehybridized to cDNA probes for TGF-131 (Panel I), TGF-132 (panel
II) and TGF-133 (Panel III). TGF-13 content of RNA isolated from cells interacted with normal albumin (Lane 1) or AGE (Lane 2) were compared.
Variation in RNA loading was determined by the intensity of the 18S band (final panel).
Fig. 9. Northern blot analysis of NOD mesangial cell TGF-3 mRNA content. RNA isolated from NOD mesangial cells was probed with specific cDNA
probes for TGF-f31 (panel I) TGF-p2 (panel H) and TGF. 133 (panel III). The steady-state TGF-13 mRNA content in cells stimulated by normal albumin
(lane 1) and cells interacted with glycosylated albumin (lane 2) were compared. Variation in RNA loading was determined by the intensity of the 18S
band (final panel).
normal rat glomeruli express high levels of TGF-131 and TGF-f32
mRNA, suggesting that TGF-13 may have an intrinsic regulatory
role in this species [46, 47]. In humans, TGF-/31 protein was also
demonstrated in advanced diabetic lesions wherein injury and
sclerotic changes were well established [25]. These results strongly
suggest that local TGF-f3 effects may influence the genesis of
diabetic nephrosclerosis.
In normal mice, in vivo renal TGF-/3 protein or mRNA is not
easily demonstrable [48}. In this study, we examined the early
changes in renal TGF-!3 mRNA and protein content using spe-
ciesspecific cDNA probes in a spontaneous model of diabetes.
Although TGF-f31 encoding mRNA is present in normoglycemic
NOD renal cortices, its relative abundance did not increase
significantly with hyperglycemia. Moreover, by Western blot anal-
ysis TGF-f31 protein was not detected in normoglycemic NOD
mouse kidney tissues. A TGF-133 mRNA signal was never de-
tected in renal tissues.
In contrast, renal TGF-!32 mRNA and protein was detected at
very low levels in normoglycemic NOD mice. The levels of renal
TGF-132 mRNA and protein product dramatically increased in
intensity within 5 to 10 days of the onset of detectable glycosuria.
Significantly, renal TGF-132 proteins were produced both as
monomers and as the more mature, biologically active dimers
[48—501. In contrast, diabetic NOD renal tissues contain only
slightly increased levels of TGF-/31 protein. In our study, the use
of suboptimal doses of insulin failed to effect a change in renal
TGF-f32 mRNA or protein content. Previous reports showed that
insulin therapy reduced but did not normalize renal TGF-J31
content in STZ-induced diabetic rats [25]. Perhaps the beneficial
results of strict glycemic control as observed in the DCCT trial are
mediated through greater changes in renal TGF-/3 levels [50]. It
remains to be determined if stringent blood glucose control in
NOD mice leads to normalization of renal TGF-f3 levels. These
results may help explain the necessity of strict glycemic control in
diabetes for the prevention of end organ damage.
The mechanisms underlying differential accumulation of
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TGF-13 isoforms in diabetic NOD renal tissues are unclear.
Therefore, we have attempted to correlate our in vivo findings
with an in vitro analysis of TGF-13 metabolism in a kidney-derived
mesangial cell culture model. To avoid any potential cellular
anomalies inherent in the autoimmune NOD mouse strain, me-
sangial cell cultures were established from both autoimmune
NOD and normal BALB/c mouse strains and compared for
TGF-j3 regulation. Within 24 hours, isolated mouse mesangial
cells secrete bioactive TGF-/3 following AGE stimulation. By
Northern blot analysis, within 24 hours AGE stimulation of both
NOD and BALB/c mesangial cells resulted predominantly in a
rise in the steady state levels of TGF-/32 mRNA. Although
previous studies demonstrated that both TGF-f3 and AGE mod-
ified proteins independently inhibit mesangial cell growth, to our
knowledge this is the first demonstration directly linking AGE
with TGF-13 mRNA and protein metabolism [51]. In contrast to
other reports, in our studies hyperglycemia alone failed to elicit
detectable mesangial cell TGF-/3 secretion [52]. These differences
may be due to the use of alternate TGF-/3 bioassays perhaps
having different sensitivities or the time after stimulation when
TGF-13 activity was determined. Since murine glomerular cells
have specific cell surface receptors for AGE which induce an
increase in matrix production, our results suggest that the patho-
genic potential of AGE's may be mediated in part via stimulation
of TGF-13. Since TGF-f3 receptors are present on mouse glomer-
ular endothelial, mesangial and epithelial cells, locally produced
TGF-/3 should be active on these cell types [45]. The localization
of NOD TGF-13 expression to glomeruli and the interstitium by
immunohistochemistry suggests that this cytokine is critically
positioned to mediate both the glomerular and interstitial scarring
observed in diabetic nephropathy.
Differential TGF-13 isoform expression has been noted both in
normal mouse fibroblasts and keratinocytes, as well as in human
ocular and liver tissues undergoing pathological fibrosis [53, 54].
Indeed, in human proliferative retinopathy, a disorder character-
ized by excessive intraocular fibrosis, TGF-J32 is the predominant
isoform of TGF-f3 protein locally produced. States of severe water
deprivation in mice causes a selective increase in TGF-j32 accu-
mulation within the juxtaglomerular apparatus of mouse kidney
[55]. None of our mice demonstrated a similar severe loss in body
weight and no TGF-/32 was noted within the JGA in diabetic
NOD mice. Therefore, the mechanisms leading to TGF-132 accu-
mulation in dehydration or diabetes appear to be different.
Although our studies were performed in very early diabetic
NOD mice, a significant accumulation of circulating glycosylated
hemoglobin, an indirect reflection of AGE formation, was de-
tected [38]. It may be possible that the continuous formation of
AGE in vivo may lead to a heightened renal TGF-/3 response and
the appearance of other TGF-13 isoforms later in disease. This
may explain the lack of renal TGF-133 mRNA in early diabetic
NOD renal tissues and its prominance in mesangial cell cultures.
To avoid severe diabetic metabolic disturbances such as dehy-
dration, ketosis and wasting, our studies were deliberately per-
formed in very early diabetic NOD mice (< 10 days) or mice given
small doses of insulin. Moreover, careful renal perfusions with
PBS and cortical dissection also limited blood and medullary
tissue contamination in our specimens. This may be an important
factor since platelets are a rich source of TGF-f31 product. Since
the immunohistochemical studies were performed with a panre-
active anti-TGF-13 Mab, other TGF-/3 proteins may be present
within diabetic NOD renal tissues in the absence of concomitant
changes in mRNA content. However, the lack of significant
TGF-131 protein on Western blot analysis and the absence of a
TGF-J33 mRNA signal suggest that TGF-/32 may be the major
isoform of TGF-13 that increases in the earliest stages of NOD
diabetes in vivo. Although the early renal TGF-p2 changes
described herein may reflect a species selective process, these data
suggest that the study of renal TGF-13 isoform expression in early
diabetes may prove insightful in human disease. As previously
suggested, mechanisms designed to prevent TGF-f3 formation or
action may aid in the ultimate prevention of diabetic renal disease.
The NOD mouse model may provide a valuable tool to dissect this
process and provide clinically relevant therapeutic options.
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